Publications by authors named "Bruce D Cheson"

Claim this Profile
I
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma.
Chaitra Ujjani, Hongkun Wang, Catherine Broome, Ajay K Gopal, Stephen D Smith, Bruce D Cheson

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results.
Bruce D Cheson, Nancy L Bartlett, Betsy Knopf, Hun J Lee, Ranjana H Advani

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia.
Bruce D Cheson, Jeff P Sharman

JCO Oncol Pract· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease.
Ayushi Chauhan, Catherine Lai, Frank Kuhr, Heidi Simmons, Bruce D Cheson

Clin Lymphoma Myeloma Leuk· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.
Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, Susan M Geyer, Scott E Smith, Bruce D Cheson

Blood Adv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.
Sarah C Rutherford, Jun Yin, Levi D Pederson, Kristie A Blum, Peter Martin, Bruce D Cheson

Blood Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A man's best friend is his PET.
Bruce D Cheson

Blood· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours.
Cristina Nanni, Carsten Kobe, Bettina Baeßler, Christian Baues, Ronald Boellaard, Bruce D Cheson

Lancet Haematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.
Anas Younes, John M Burke, Bruce D Cheson, Catherine S Diefenbach, Silvia Ferrari

Blood Adv· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Sarah C Rutherford, Jun Yin, Levi Pederson, Gabriela Perez Burbano, Betsy LaPlant, Bruce D Cheson

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Slaying the real giants in the war on chronic lymphocytic leukemia.
Bruce D Cheson

Chin Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes.
David G Proudman, Deepshekhar Gupta, Dave Nellesen, Jay Yang, Beth A Kamp, Bruce D Cheson

Oncotarget· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, Seongho Kim, Krish Patel, Bruce D Cheson

Clin Lymphoma Myeloma Leuk· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.
Alex F Herrera, Manish R Patel, John M Burke, Ranjana Advani, Bruce D Cheson

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Sriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, Nathan H Fowler, Judith Trotman, Bruce D Cheson

Cancer Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S Fenske, Bruce D Cheson

Blood Adv· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Role of Functional Imaging in the Management of Lymphoma.
Bruce D Cheson, Michel Meignan

Curr Oncol Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Kerry A Rogers, Philip A Thompson, John N Allan, Morton Coleman, Jeff P Sharman, Bruce D Cheson

Haematologica· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, Nicole Lamanna, John M Pagel, Bruce D Cheson

Blood· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, Bruce D Cheson

J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffuse large B-cell lymphoma: new targets and novel therapies.
Bruce D Cheson, Grzegorz Nowakowski, Gilles Salles

Blood Cancer J· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.
Ayushi F Chauhan, Bruce D Cheson

Cancer Manag Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Bruce D Cheson, Anthony R Mato

Clin Adv Hematol Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Bruce D Cheson

Clin Adv Hematol Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia: Q&A.
Bruce D Cheson, Anthony R Mato

Clin Adv Hematol Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis